IMNN 8-K SEC Filing Analysis

Latest settled — T+20d

IMNN ▼ -6.12% at T+20d

NEUTRAL call ✗ call lost -6.12% · α vs SPY -15.55% · entry $2.94 → $2.76

Next anchor: T+60d in 11d

Last close $2.02 (close Jun 12) · -31.29% from $2.94 entry

Entry anchored
Mar 30, 12:18 PM ET
via Databento tick

T+1d

+1.70%

call +1.70% · α +0.95%

$2.99

settled 3mo ago

T+5d

+6.46%

call +6.46% · α +2.52%

$3.13

settled 2mo ago

T+20d

-6.12%

call -6.12% · α -15.55%

$2.76

settled 7w ago

T+60d

—

call — · α —

—

in 11d

Price Chart

Loading chart...

Executive Summary

Imunon reported a 2025 net loss of $14.5 million (EPS $-6.83), missing consensus by 55.9%, but highlighted improved Phase 2 survival data showing a 14.7-month overall survival benefit for its ovarian cancer therapy IMNN-001. The company raised $7.0 million in December 2025 and ended the year with $8.8 million in cash.

Actionable Insight

Despite the EPS miss, the improved survival data strengthens the clinical case for IMNN-001. Monitor enrollment progress in the Phase 3 OVATION 3 trial and upcoming interim analyses as key catalysts. The recent capital raise extends the runway but further dilution may be needed before potential approval.

Key Facts

Net loss for 2025 was $14.5 million, or $6.83 per share, compared to a net loss of $18.6 million, or $16.94 per share, in 2024
Final Phase 2 data showed a median 14.7-month overall survival benefit (45.1 vs 30.4 months) for IMNN-001 plus chemotherapy vs chemotherapy alone
Women receiving IMNN-001 plus PARP inhibitors showed a 24.2-month survival benefit (65.6 vs 41.4 months)
Company completed a $7.0 million registered direct offering in December 2025
Cash and cash equivalents were $8.8 million as of December 31, 2025

Financial Impact

Net loss narrowed to $14.5M from $18.6M year-over-year, but EPS of $-6.83 missed consensus of $-1.28 by 55.9%

epsnet_losscash

Risk Factors

EPS miss of 55.9% indicates ongoing funding challenges despite cost reductions
Phase 3 trial success is not guaranteed despite promising Phase 2 data
Additional capital raises could lead to shareholder dilution

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-013816
Document: form8-k.htm	0001493152-26-013816
Document: 0001493152-26-013816-index-headers.html	0001493152-26-013816
Document: 0001493152-26-013816-index.html	0001493152-26-013816
Document: 0001493152-26-013816.txt	0001493152-26-013816
8-K Data (Synthetic)	0001493152-26-013816

5 reports for IMNN

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IMNN — sortable, filterable
	Type				Now
Jun 4, 2026 10d ago	8-K BEARISH ★ 6/10	$2.10 $2.06	▲ +1.90%	▼ −0.69%	$2.02 (+3.81%)
May 12, 2026 4w ago	8-K BULLISH ★ 6/10	$2.70 $2.60	▼ −3.70%	▼ −4.28%	$2.02 (−25.19%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 2/10	$2.80 $2.77	▼ −1.07%	▼ −1.87%	$2.02 (−27.86%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$2.94 $2.99	▲ +1.70%	▲ +0.95%	$2.02 (−31.29%)
Mar 24, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$2.94 $2.78	▼ −5.44%	▼ −6.01%	$2.02 (−31.29%)

US Market Status

Market Closed — Opens in 5h 5m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access